Circulating cell-free miRNAs as biomarker for triple-negative breast cancer

British Journal of Cancer

Volumn 112, Issue 11, 2015, Pages 1751-1759

  Shin, V Y ^a   Siu, J M ^a   Cheuk, I ^a   Ng, E K O ^a   Kwong, A ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Hong Kong Hereditary Breast Cancer Family Registry   (Hong Kong)

Author keywords

biomarker; circulating cell free miRNA; miR 199a 5p; triple negative breast cancer

Indexed keywords

MICRORNA; MICRORNA 16; MICRORNA 199A 5P; MICRORNA 21; MICRORNA 342 3P; MICRORNA 92A 3P; UNCLASSIFIED DRUG; MIRN199 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER SCREENING; CANCER STAGING; CIRCULATING TUMOR CELL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; AGED; BLOOD; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84930048540     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.143     Document Type: Article

References (34)

1. Boyle P. (2012). Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(Suppl 6): vi7-12
2. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sultmann H. (2011). Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128(3): 608-616
3. Calin GA, Croce CM. (2006). MicroRNA signatures in human cancers. Nat Rev Cancer 6(11): 857-866
4. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, Burrows E, Bernard PS, Hoadley KA, Perou CM, Winer EP. (2012). TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30(21): 2615-2623
5. Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K. (2013). Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 8(2): e55910
6. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. (2007). Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1): 4429-4434
7. Foulkes WD, Smith IE, Reis-Filho JS. (2010). Triple-negative breast cancer. N Engl J Med 363(20): 1938-1948
8. Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, Carasi S, Palmieri D, Costinean S, Shapiro CL, Huebner K, Croce CM. (2014). Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci USA 111(12): 4536-4541
9. He XJ, Ma YY, Yu S, Jiang XT, Lu YD, Tao L, Wang HP, Hu ZM, Tao HQ. (2014). Up-regulated miR-199a-5p in gastric cancer functions as an oncogene and targets klotho. BMC Cancer 14: 218
10. Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y, Tang J, Chen X, Dai J, Wei Q, Zhang C, Shen H. (2012). Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis 33(4): 828-834
11. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzman M, Grueso J, Rodriguez O, Calvo MT, Aura C, Diez O, Rubio IT, Perez J, Rodon J, Cortes J, Ellisen LW, Scaltriti M, Baselga J. (2012). PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2(11): 1036-1047
12. Kalscheuer S, Zhang X, Zeng Y, Upadhyaya P. (2008). Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 29(12): 2394-2399
13. Lai CT, Ng EK, Chow PC, Kwong A, Cheung YF. (2013). Circulating microRNA expression profile and systemic right ventricular function in adults after atrial switch operation for complete transposition of the great arteries. BMC Cardiovasc Disord 13: 73
14. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, Ursin G. (2011). Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women. J Clin Oncol 29(33): 4373-4380
15. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim Jr. HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M. (2012). Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30(15): 1879-1887
16. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30): 10513-10518
17. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS, Sung JJ. (2009). Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58(10): 1375-1381
18. Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law WL, Law SY, Poon RT, Kwong A. (2013). Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One 8(1): e53141
19. Raimondi L, Amodio N, Di Martino MT, Altomare E, Leotta M, Caracciolo D, Gulla A, Neri A, Taverna S, D'Aquila P, Alessandro R, Giordano A, Tagliaferri P, Tassone P. (2014). Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-Tumor activity. Oncotarget 5(10): 3039-3054
20. Rivas MA, Venturutti L, Huang YW, Schillaci R, Huang TH, Elizalde PV. (2012). Downregulation of the tumor-suppressor miR-16 via progestinmediated oncogenic signaling contributes to breast cancer development. Breast Cancer Res 14(3): R77
21. Serpico D, Molino L, Di Cosimo S. (2014). microRNAs in breast cancer development and treatment. Cancer Treat Rev 40(5): 595-604
22. Shapira I, Oswald M, Lovecchio J, Khalili H, Menzin A, Whyte J, Dos Santos L, Liang S, Bhuiya T, Keogh M, Mason C, Sultan K, Budman D, Gregersen PK, Lee AT. (2014). Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer 110(4): 976-983
23. Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA, Winer EP. (2015). Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 33(1): 13-21
24. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE. (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28(7): 1145-1153
25. Su SF, Chang YW, Andreu-Vieyra C, Fang JY, Yang Z, Han B, Lee AS, Liang G. (2013). miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene 32(39): 4694-4701
26. Terao M, Fratelli M, Kurosaki M, Zanetti A, Guarnaccia V, Paroni G, Tsykin A, Lupi M, Gianni M, Goodall GJ, Garattini E. (2011). Induction of miR-21 by retinoic acid in estrogen receptor-positive breast carcinoma cells: biological correlates and molecular targets. J Biol Chem 286(5): 4027-4042
27. Tilghman SL, Bratton MR, Segar HC, Martin EC, Rhodes LV, Li M, McLachlan JA, Wiese TE, Nephew KP, Burow ME. (2012). Endocrine disruptor regulation of microRNA expression in breast carcinoma cells. PLoS One 7(3): e32754
28. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E. (2010). Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 102(7): 1174-1179
29. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7): 2257-2261
30. von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B. groups GA-Bs. (2014). Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto) dagger. Ann Oncol 25(12): 2363-2372
31. Wang Y, Jiang L, Ji X, Yang B, Zhang Y, Fu XD. (2013). Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor microRNA miR-15a/miR-16-1 in hepatocytes. J Biol Chem 288(25): 18484-18493
32. Yi H, Liang B, Jia J, Liang N, Xu H, Ju G, Ma S, Liu X. (2013). Differential roles of miR-199a-5p in radiation-induced autophagy in breast cancer cells. FEBS Lett 587(5): 436-443
33. Zeng RC, Zhang W, Yan XQ, Ye ZQ, Chen ED, Huang DP, Zhang XH, Huang GL. (2013). Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer. Med Oncol 30(1): 477
34. Zhao X, He L, Li T, Lu Y, Miao Y, Liang S, Guo H, Bai M, Xie H, Luo G, Zhou L, Shen G, Guo C, Bai F, Sun S, Wu K, Nie Y, Fan D. (2014). SRF expedites metastasis and modulates the epithelial to mesenchymal transition by regulating miR-199a-5p expression in human gastric cancer. Cell Death Differ 21(12): 1900-1913